MedTrace Logo

Study of V117957 in Overactive Bladder Syndrome

NCT06024642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-06-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.

Conditions

  • Overactive Bladder Syndrome

Interventions

DRUG

V117957

V117957 1 mg - 1 tablet taken orally at bedtime.

DRUG

Placebo

Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.

Sponsors & Collaborators

  • Purdue Pharma LP

    collaborator INDUSTRY

  • Imbrium Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2024-05-21
Completion
2024-05-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06024642 on ClinicalTrials.gov